Exelixis Begins Ph III Trial of Cabometyx in Refractory Thyroid Cancer

Exelixis Begins Ph III Trial of Cabometyx in Refractory Thyroid Cancer

Source: 
CP Wire
snippet: 
  • Thyroid cancer is the most rapidly increasing cancer diagnosis in the US with incidence tripling over the last 30 years
  • Cabometyx is approved for renal cell carcinoma and hepatocellular carcinoma
  • It has orphan drug status in the US for advanced hepatocellular carcinoma